Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02037126 · ClinicalTrials.gov registry record · Phase 2
Psilocybin-facilitated Treatment for Cocaine Use
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02037126 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 40 participants.
The verdict
NCT02037126, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the feasibility and estimate the efficacy of psilocybin-facilitated treatment for cocaine use. We also will monitor the impact of psilocybin-facilitated treatment on the use of other drugs and outcomes relevant to cocaine involvement. MRI assessment is a unique aspect of this study. As a potential biological mechanism of psilocybin's effect includes changes in default mode network functional connectivity (Carhart-Harris et al., 2012), we will determine if psilocybin's therapeutic effects are mediated by such changes. Moreover, as Glx (a brain metabolite that reflects glutamate) abnormalities have been shown to play a role in cocaine addiction, we will determine if psilocybin impacts Glx in the anterior cingulate cortex and hippocampus.
Interventions
- DRUG Psilocybin
- DRUG Diphenhydramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-05 |
| Est. Completion | 2024-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02037126
The ClinicalTrials.gov registry entry for NCT02037126 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Psilocybin is the first listed.
NCT02037126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02037126 about?
NCT02037126 is a clinical study titled "Psilocybin-facilitated Treatment for Cocaine Use". The primary purpose of this study is to evaluate the feasibility and estimate the efficacy of psilocybin-facilitated treatment for cocaine use. We also will monitor the impact of psilocybin-facilitated treatment on the use of other drugs and outcomes relevant to cocaine involvement. MRI assessment ...
What is the current status of trial NCT02037126?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2015-05. Estimated completion is 2024-05.
What interventions are being tested in trial NCT02037126?
The interventions under investigation include: Psilocybin (DRUG), Diphenhydramine (DRUG).
Who is sponsoring clinical trial NCT02037126?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.